Trial Profile
A Multicentre, Randomised, Double-blind (Sponsor-unblinded), Placebo-controlled, Repeat Dose Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Active Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 17 Apr 2020 Results assessing the safety and tolerability, PK, PD, and preliminary efficacy of GSK2982772 published in the Clinical Pharmacology and Therapeutics
- 16 Jan 2018 Status changed from recruiting to completed.
- 23 May 2017 Planned number of patients changed from 30 to 54.